Related Experiment Video
Updated: Jul 4, 2025

06:38
Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity AIDN: A Translational Neuroscience Approach
Published on: June 11, 2017
11.3K
The First Steps on AOPs' Concepts, Development, and Applications in Teratology
Leonardo Vieira1,2, Terezinha Souza2, Davi Farias3,4
1Post-Graduation Program in Biochemistry, Department of Biochemistry and Molecular Biology, Federal University of Ceará, Fortaleza, Brazil.
Methods in Molecular Biology (Clifton, N.J.)
|January 29, 2024
Summary
Adverse Outcome Pathways (AOPs) provide a framework for understanding how molecular events lead to adverse health effects. Standardized AOP development enhances toxicity testing and reduces animal use.
Area of Science:
- Toxicology and Ecotoxicology
- Computational Biology
- Biomedical Sciences
Background:
- Adverse Outcome Pathways (AOPs) are analytical models detailing biologically linked events from molecular initiation to adverse effects.
- AOPs are built on principles of systematic review, chemical-agnosticism, modularity, networks, and living documents.
- AOPs offer applications in target investigation, cross-species extrapolation, and predicting population-specific adverse effects.
Approach:
- AOP construction requires standardization for quality, flexibility, and efficiency, adhering to OECD guidance.
- Key steps include selecting an apical endpoint or initiating molecular event and conducting systematic literature reviews.
- Utilizing OECD guidance documents ensures proper organization and construction of AOPs.
Key Points:
- AOPs serve as alternatives to animal testing, particularly for developmental malformations.
- Quantitative AOPs can predict teratogenic effects of specific substances.
- Standardized AOP development is crucial for reliable toxicity prediction.
Conclusions:
- AOPs represent a modern approach revolutionizing toxicity testing by linking molecular-level effects to apical toxic outcomes.
- This methodology facilitates prediction of adverse effects, potentially reducing reliance on traditional animal studies.
- Standardized AOP development ensures robust and efficient toxicological assessments.
Related Concept Videos
Teratogenicity
2.5K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.5K
Preclinical Development: Overview
4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Mutagenicity and Carcinogenicity
1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
Pharmacovigilance
833
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
833

